Twenty-four year spironolactone therapy in an aged patient with aldosterone-producing adenoma

in European Journal of Endocrinology
Restricted access

A case of primary aldosteronism treated with spironolactone therapy has been followed up for 24 years. This is probably the longest case of spironolactone therapy for primary aldosteronism that has ever been reported. Long-term treatment with spironolactone controlled the hypertension and prevented hypokalemic alkalosis in this patient, without any deleterious effects on steroid biosynthesis. Based on data obtained during dose reduction and subsequent withdrawal of spironolactone, it is suggested that the suppressed plasma renin activity associated with adenoma-induced aldosteronism develops prior to hypokalemia and hypertension.


     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 98 36 2
Full Text Views 53 0 0
PDF Downloads 25 0 0